Shattuck Labs, Inc. (STTK)
- Previous Close
10.49 - Open
10.52 - Bid 10.63 x 200
- Ask 10.69 x 200
- Day's Range
10.33 - 10.76 - 52 Week Range
1.33 - 11.62 - Volume
150,384 - Avg. Volume
328,561 - Market Cap (intraday)
506.893M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.93 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.75
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
www.shattucklabs.comRecent News: STTK
Performance Overview: STTK
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STTK
Valuation Measures
Market Cap
506.89M
Enterprise Value
396.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
175.24
Price/Book (mrq)
3.94
Enterprise Value/Revenue
145.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.74%
Return on Equity (ttm)
-59.40%
Revenue (ttm)
2.71M
Net Income Avi to Common (ttm)
-85.08M
Diluted EPS (ttm)
-1.93
Balance Sheet and Cash Flow
Total Cash (mrq)
114.63M
Total Debt/Equity (mrq)
2.48%
Levered Free Cash Flow (ttm)
-41.45M
Research Analysis: STTK
Company Insights: STTK
STTK does not have Company Insights